Back to discover
Drug

Bimagrumab

In clinical development
ClassActivin receptor type-2B antagonistEmerging researchLate-stage development
RxNorm1677237ChEMBLCHEMBL3137353UNIIN15SW1DIV8
2
Research papers
2
Active clinical trials
Activin receptor type-2B
Primary target
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Effect of Tirzepatide and Bimagrumab on Body Composition, Insulin Sensitivity, and Bone in Adults With Obesity

Clinical trial2026-03-27Results expected Q4 2028 · ClinicalTrials.gov

Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial.

Research2026-03-02Nature medicine

A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study of Bimagrumab and Tirzepatide, Alone or in Combination, to Investigate the Efficacy and Safety in Adult Participants With Obesity or Overweight Without Type 2 Diabetes

Clinical trial2026-01-16Primary completion · ClinicalTrials.gov

A Phase 1, Relative Bioavailability Study of Bimagrumab (LY3985863) Test and Reference Materials, and Bimagrumab Test Material Coadministration and Coformulation With Tirzepatide (LY900042), in Healthy Participants

Clinical trial2025-09-26Completed · ClinicalTrials.gov

A Randomized, Double-Blind, Placebo-Controlled Multi-Center Study of Intravenous Bimagrumab, Alone or in Addition to Open Label Subcutaneous Semaglutide, to Investigate the Efficacy and Safety in Overweight or Obese Men and Women

Clinical trial2025-07-18Results posted · ClinicalTrials.gov

A Phase 2b Double-Blind, Randomized, Placebo-Controlled Study of Bimagrumab and Tirzepatide, Alone or in Combination, to Investigate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes

Clinical trial2025-06-10Withdrawn · ClinicalTrials.gov

Antibody blockade of activin type II receptors preserves skeletal muscle mass and enhances fat loss during GLP-1 receptor agonism.

Research2024-01-11Molecular metabolism

A 28 Week, Randomized, Double-blind, Placebo-controlled, Two-part, Multi-center, Parallel Group Dose Range Finding Study to Assess the Effect of Monthly Doses of Bimagrumab 70, 210, and 700 mg on Skeletal Muscle Strength and Function in Older Adults With Sarcopenia (InvestiGAIT)

Clinical trial2021-01-05Results posted · ClinicalTrials.gov

A 24-week Double-blind Treatment and 24-week Follow-up, Randomized, Multicenter, Placebo-controlled, Phase IIa/IIb Study to Evaluate Safety and Efficacy of i.v. Bimagrumab on Total Lean Body Mass and Physical Performance in Patients After Surgical Treatment of Hip Fracture

Clinical trial2020-08-19Results posted · ClinicalTrials.gov

A 24 Week Off Drug Extension, Parallel Group, Study Assessing Durability of Effect on Skeletal Muscle Strength and Function Following a 6-month Double-blind, Placebo Controlled Study Evaluating Bimagrumab in Older Adults With Sarcopenia (InvestiGAIT Extension)

Clinical trial2020-06-16Results posted · ClinicalTrials.gov

Extension of the CBYM338B2203 Phase IIb/III Study to Evaluate the Long-term Efficacy, Safety and Tolerability of Intravenous BYM338 in Patients With Sporadic Inclusion Body Myositis

Clinical trial2018-03-13Results posted · ClinicalTrials.gov

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Bimagrumab
RxNorm CUI
1677237
ChEMBL ID
CHEMBL3137353
UNII
N15SW1DIV8
Primary mechanism
Activin receptor type-2B antagonist

Pharmacology & targets

1 target

Known molecular targets and mechanisms supported by curated pharmacology databases.

Activin receptor type-2B
ACVR2B · Q13705
ANTAGONISTActivin receptor type-2B antagonist

Clinical trials

9 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
9
registered trials across all phases
LATEST COMPLETION 2025
2
Active studies
1
Recruiting
1
Late-stage (III+)
6
Completed
1
Discontinued
PHASE DISTRIBUTIONn = 9
Phase 11Phase 27Phase 31

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

Extension of the CBYM338B2203 Phase IIb/III Study to Evaluate the Long-term Efficacy, Safety and Tolerability of Intravenous BYM338 in Patients With Sporadic Inclusion Body Myositis

CompletedPH IIINovartis Pharmaceuticalsn=2112017

Recent completions

Trials that read out recently, adding to the completed evidence base.

A Phase 1, Relative Bioavailability Study of Bimagrumab (LY3985863) Test and Reference Materials, and Bimagrumab Test Material Coadministration and Coformulation With Tirzepatide (LY900042), in Healthy Participants

CompletedPH IEli Lilly and Companyn=1252025

A Randomized, Double-Blind, Placebo-Controlled Multi-Center Study of Intravenous Bimagrumab, Alone or in Addition to Open Label Subcutaneous Semaglutide, to Investigate the Efficacy and Safety in Overweight or Obese Men and Women

CompletedPH IIEli Lilly and Companyn=5072025

A 24 Week Off Drug Extension, Parallel Group, Study Assessing Durability of Effect on Skeletal Muscle Strength and Function Following a 6-month Double-blind, Placebo Controlled Study Evaluating Bimagrumab in Older Adults With Sarcopenia (InvestiGAIT Extension)

CompletedPH IINovartis Pharmaceuticalsn=1602018

A 24-week Double-blind Treatment and 24-week Follow-up, Randomized, Multicenter, Placebo-controlled, Phase IIa/IIb Study to Evaluate Safety and Efficacy of i.v. Bimagrumab on Total Lean Body Mass and Physical Performance in Patients After Surgical Treatment of Hip Fracture

CompletedPH IINovartis Pharmaceuticalsn=2512018

A 28 Week, Randomized, Double-blind, Placebo-controlled, Two-part, Multi-center, Parallel Group Dose Range Finding Study to Assess the Effect of Monthly Doses of Bimagrumab 70, 210, and 700 mg on Skeletal Muscle Strength and Function in Older Adults With Sarcopenia (InvestiGAIT)

CompletedPH IINovartis Pharmaceuticalsn=2172018

Extension of the CBYM338B2203 Phase IIb/III Study to Evaluate the Long-term Efficacy, Safety and Tolerability of Intravenous BYM338 in Patients With Sporadic Inclusion Body Myositis

CompletedPH IIINovartis Pharmaceuticalsn=2112017

Research activity

2 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Publications over time
20242026
Major research themes8
Obesity2Activin Receptors, Type II1Antibodies, Monoclonal1Antibodies, Monoclonal, Humanized1Glucagon-Like Peptide-1 Receptor1Glucagon-Like Peptide-1 Receptor Agonists1Glucagon-Like Peptides1Proto-Oncogene Proteins c-akt1
Journals, researchers & institutions
Top journals
  • Molecular metabolism1
  • Nature medicine1
Leading researchers
  • Aronne LJ1
  • Attie KM1
  • Baur JA1
  • Calhoun R1
  • Coleman LA1
  • Dole K1
  • Drareni K1
  • Gavin M1
Leading institutions
free-text, unnormalised
  • Institute for Diabetes1
  • Optimal Clinical Trials1
  • Pennington Biomedical Research Center1

Related diseases

1 conditions

Regulator-approved indications and conditions co-mentioned with this drug across the research literature. Number shows shared papers.

Active research areas
Obesity2

Related drugs

1 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Semaglutide

Studied across 3 of the same disease areas as Bimagrumab in the shared literature.

3 shared diseases1 shared paper
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials